New P2Y12 blockers

被引：35

作者：

Cattaneo, M. ^{[1
]}

机构：

[1] Univ Milan, Osped San Paolo, Unita Med 3, I-20142 Milan, Italy

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷

关键词：

acute coronary syndromes; adenosine diphosphate; antiplatelet drugs; cangrelor; clopidogrel; P2Y12; platelet aggregation; prtasugrel; thienopyridines; ticagrelor; ACTIVE METABOLITE; EFFICIENT GENERATION; PLATELET INHIBITION; CLOPIDOGREL; PRASUGREL; RECEPTOR; ASPIRIN; GREATER; SAFETY; TOLERABILITY;

D O I：

10.1111/j.1538-7836.2009.03382.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A number of new antiplatelet agents currently in development are anticipated to improve clinical outcomes and safety benefits in patients with acute coronary syndrome (ACS). This article reviews the pharmacology and clinical development of three of these agents: prasugrel, cangrelor, and ticagrelor. Prasugrel, a third-generation, oral thienopyridine, has been shown to be superior to clopidogrel, the current gold standard, in preventing ischemic events in patients with ACS undergoing percutaneous coronary intervention (PCI), although the bleeding rate was higher. Cangrelor, a chemical analog of adenosine triphosphate, is a potent direct platelet P2Y(12) antagonist. In development as an intravenous agent, cangrelor is currently being evaluated in two phase III studies in patients requiring PCI. Ticagrelor is the first of a new class of orally available antiplatelet agents antagonizing the effects of ADP mediated by P2Y(12); it is currently being studied in a phase III trial in patients with ACS.

引用

页码：262 / 265

页数：4

共 18 条

[1]

[Anonymous], ADP RECEPTORS ANTAGO

[2] A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation [J].

Brandt, John T. ;

Payne, Christopher D. ;

Wiviott, Stephen D. ;

Weerakkody, Govinda ;

Farid, Nagy A. ;

Small, David S. ;

Jaknbowski, Joseph A. ;

Naganuma, Hideo ;

Winters, Kenneth J. .

AMERICAN HEART JOURNAL, 2007, 153 (01) :66.e9-66.e16

[3] Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial [J].

Cannon, Christopher P. ;

Husted, Steen ;

Harrington, Robert A. ;

Scirica, Benjamin M. ;

Emanuelsson, Hakan ;

Storey, Robert F. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (19) :1844-1851

[4] Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin [J].

Cattaneo, M. ;

Lecchi, A. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (03) :577-582

[5]

Cattaneo M, 2006, PLATELETS, P201

[6] Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting [J].

Chen, LQ ;

Bracey, AW ;

Radovancevic, R ;

Cooper, JR ;

Collard, CD ;

Vaughn, WK ;

Nussmeier, NA .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 128 (03) :425-431

[7] Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention:: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial [J].

Greenbaum, AB ;

Grines, CL ;

Bittl, JA ;

Becker, RC ;

Kereiakes, DJ ;

Gilchrist, IC ;

Clegg, J ;

Stankowski, JE ;

Grogan, DR ;

Harrington, RA ;

Emanuelsson, H ;

Weaver, WD .

AMERICAN HEART JOURNAL, 2006, 151 (03) :689.e1-689.e10

[8] Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction:: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial [J].

Greenbaum, Adam B. ;

Ohman, E. Magnus ;

Gibson, C. Michael ;

Borzak, Steven ;

Stebbins, Amanda L. ;

Lu, Mei ;

Le May, Michel R. ;

Stankowski, Jill E. ;

Emanuelsson, Hakan ;

Weaver, W. Douglas .

AMERICAN HEART JOURNAL, 2007, 154 (04) :702-709

[9] The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting [J].

Hongo, RH ;

Ley, J ;

Dick, SE ;

Yee, RR .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (02) :231-237

[10] Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:: a double-blind comparison to clopidogrel with aspirin [J].

Husted, S ;

Emanuelsson, H ;

Heptinstall, S ;

Sandset, PM ;

Wickens, M ;

Peters, G .

EUROPEAN HEART JOURNAL, 2006, 27 (09) :1038-1047

← 1 2 →